Kineta, Inc, a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology announced the appointment of Keith Baker as the Company’s new Chief Financial Officer (CFO).
“It is a pleasure to welcome Keith to our management team at this pivotal time for Kineta,” said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. “Keith’s experience as an accomplished CFO with deep financial and operational expertise along with a solid track record of building and financing both public and private companies will be invaluable as we transition into a publicly-traded company.”
Mr. Baker brings more than 30 years of financial expertise to Kineta in corporate finance, public accounting and Securities and Exchange Commission (SEC) reporting. Prior to joining Kineta, Mr. Baker served as CFO of several technology companies including Element Data, Inc., a decision intelligence technology firm, and Zemax, LLC, a software company in optical and illumination design. Previously, Mr. Baker led SEC financial reporting and the Sarbanes-Oxley compliance program at Targeted Genetics Corporation (now Armata Pharmaceuticals), a biotechnology company focused on developing anti-bacterial therapeutics. Mr. Baker started his career in public accounting as an auditor at Deloitte & Touche LLP.
“It’s an exciting time to join Kineta’s leadership team, with the Company well-positioned to achieve key strategic goals in closing the reverse merger with Yumanity Therapeutics and expecting to initiate the first-in-human clinical trial of KVA12.1 this quarter,” said Mr. Baker. “I look forward to contributing to Kineta’s mission to transform patient’s lives with next-generation immunotherapies, while providing my expertise to achieve the Company’s financial goals.”